Human cytomegalovirus (HCMV)-specific CD4+ T cells are polyfunctional and can respond to HCMVinfected dendritic cells in vitro

Journal of Virology

Volumn 91, Issue 6, 2017, Pages

  Jackson, Sarah E ^a   Sedikides, George X ^a   Mason, Gavin M ^a,b   Okecha, Georgina ^a   Wills, Mark R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ageing; Antiviral; CD4+ T cells; Human cytomegalovirus (HCMV); Polyfunctional

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GLYCOPROTEIN B; INTERLEUKIN 10; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN IE1; PROTEIN IE2; PROTEIN PP71; PROTEIN US3; UNCLASSIFIED DRUG; VIRAL PROTEIN; IL10 PROTEIN, HUMAN; VIRUS ANTIGEN;

ADULT; AGED; AGING; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; NONHUMAN; TH1 CELL; CYTOMEGALOVIRUS; IMMUNOLOGY; MIDDLE AGED; SECRETION (PROCESS); YOUNG ADULT;

ADULT; AGED; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85014114674     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02128-16     Document Type: Article

References (71)

1. Gandhi MK, Khanna R. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725-738. https://doi.org/10.1016/S1473-3099(04)01202-2.
2. Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J Gen Virol 87:1763-1779. https://doi.org/10.1099/vir.0.81891-0.
3. Crough T, Khanna R. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22:76-98. https://doi.org/10.1128/CMR.00034-08.
4. Jackson S, Mason G, Wills M. 2011. Human cytomegalovirus immunity and immune evasion. Virus Res 157:151-160. https://doi.org/10.1016/j.virusres.2010.10.031.
5. Benedict CA, Crozat K, Degli-Esposti M, Dalod M. 2013. Host genetic models in cytomegalovirus immunology, p 259-285. In Reddehase MJ (ed), Cytomegaloviruses: from molecular pathogenesis to intervention, vol II. Caister Academic Press, Poole, United Kingdom.
6. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treat-ment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922. https://doi.org/10.1182/blood.V99.11.3916.
7. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362:1375-1377. https://doi.org/10.1016/S0140-6736(03)14634-X.
8. + T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 74:211-220. https://doi.org/10.1002/cyto.b.20420.
9. Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H. 2001. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287-1294. https://doi.org/10.1097/00007890-200105150-00018.
10. + T cells in protection against CMV disease. Blood 101:2686-2692. https://doi.org/10.1182/blood-2002-08-2502.
11. + T cell differentiation after primary infection. J Infect Dis 198:536-543. https://doi.org/10.1086/590118.
12. + T cells during primary cytomegalovirus infection. J Clin Invest 105:541-548. https://doi.org/10.1172/JCI8229.
13. + T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172: 3260-3267. https://doi.org/10.4049/jimmunol.172.5.3260.
14. Wills MR, Mason GM, Sissons JGP. 2013. Adaptive cellular immunity to human cytomegalovirus, p 142-172. In Reddehase MJ (ed), Cytomegaloviruses: from molecular pathogenesis to intervention, vol II. Caister Academic Press, Poole, United Kingdom.
15. Elkington R, Shoukry NH, Walker S, Crough T, Fazou C, Kaur A, Walker CM, Khanna R. 2004. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 34:3216-3226. https://doi.org/10.1002/eji.200425203.
16. + T cell responses. J Immunol 195:3803-3815. https://doi.org/10.4049/jimmunol.1500696.
17. + T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685. https://doi.org/10.1084/jem.20050882.
18. Sester M, Sester U, Gartner B, Kubuschok B, Girndt M, Meyerhans A, Kohler H. 2002. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 76:3748-3755. https://doi.org/10.1128/JVI.76.8.3748-3755.2002.
19. + T-cell repertoire. J Virol 81:7759-7765. https://doi.org/10.1128/JVI.01262-06.
20. + CD28+ granzyme Bα, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 173:1834-1841. https://doi.org/10.4049/jimmunol.173.3.1834.
21. + CD45RA+ CD27 T cells: the potential involvement of interleukin-7 in this process. Immunology 132:326-339. https://doi.org/10.1111/j.1365-2567.2010.03386.x.
22. + T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 175:8218-8225. https://doi.org/10.4049/jimmunol.175.12.8218.
23. + T-cell reconstitution following stem cell transplantation through the use of HLA class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation. Haematologica 100:e318-e322. https://doi.org/10.3324/haematol.2015.123687.
24. + T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J Immunol 173:5843-5851. https://doi.org/10.4049/jimmunol.173.9.5843.
25. + CD27+ CD28+ T cells. Virology 398:158-167. https://doi.org/10.1016/j.virol.2009.11.038.
26. + CTLs ex vivo. J Immunol 168:5954-5958. https://doi.org/10.4049/jimmunol.168.11.5954.
27. Dirks J, Tas H, Schmidt T, Kirsch S, Gärtner BC, Sester U, Sester M. 2013. PD-1 analysis on CD28+ CD27+ CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant 13:3132-3141. https://doi.org/10.1111/ajt.12480.
28. Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. 2013. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine 31:685-690. https://doi.org/10.1016/j.vaccine.2012.11.041.
29. Vescovini R, Biasini C, Telera AR, Basaglia M, Stella A, Magalini F, Bucci L, Monti D, Lazzarotto T, Dal Monte P, Pedrazzoni M, Medici MC, Chezzi C, Franceschi C, Fagnoni FF, Sansoni P. 2010. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status. J Immunol 184:3242-3249. https://doi.org/10.4049/jimmunol.0902890.
30. + T lymphocytes with cellular maturation. J Exp Med 203:2865-2877. https://doi.org/10.1084/jem.20052246.
31. + T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 111:2053-2061. https://doi.org/10.1182/blood-2007-04-079863.
32. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, Kern F. 2012. Polyfunctional T cells accumulate in large human cytomegalovirusspecific T cell responses. J Virol 86:1001-1009. https://doi.org/10.1128/JVI.00873-11.
33. Cicin-Šain L, Sylwester AW, Hagen SI, Siess DC, Currier N, Legasse AW, Fischer MB, Koudelka CW, Axthelm MK, JNikolich-Žugich Picker LJ. 2011. Cytomegalovirus-specific T cell immunity is maintained in immunosenescent rhesus macaques. J Immunol 187:1722-1732. https://doi.org/10.4049/jimmunol.1100560.
34. Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJL, Onengut-Gumuscu S, Kidd BA, Maecker HT, Concannon P, Dekker CL, Thomas PG, Davis MM. 2015. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med 7:281ra43. https://doi.org/10.1126/scitranslmed.aaa2293.
35. Marandu TF, Finsterbusch K, Kröger A, Cicin-Šain L. 2014. Mouse CMV infection delays antibody class switch upon an unrelated virus challenge. Exp Gerontol 54:101-108. https://doi.org/10.1016/j.exger.2014.01.017.
36. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC. 2009. The cytolytic enzymes granzyme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 85:88-97. https://doi.org/10.1189/jlb.0208107.
37. Weltevrede M, Eilers R, de Melker HE, van Baarle D. 2016. Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review. Exp Gerontol 77:87-95. https://doi.org/10.1016/j.exger.2016.02.005.
38. Denkinger MD, Leins H, Schirmbeck R, Florian M, Geiger H. 2015. HSC aging and senescent immune remodeling. Trends Immunol 36:815-824. https://doi.org/10.1016/j.it.2015.10.008.
39. Kline KA, Bowdish DME. 2016. Infection in an aging population. Curr Opin Microbiol 29:63-67. https://doi.org/10.1016/j.mib.2015.11.003.
40. Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, Moss PAH, Medical Research Council Cognitive Function and Ageing Study. 2013. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell 12:381-387. https://doi.org/10.1111/acel.12059.
41. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. 2011. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 6:e16103. https://doi.org/10.1371/journal.pone.0016103.
42. + T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. PLoS One 8:e71498. https://doi.org/10.1371/journal.pone.0071498.
43. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. 2012. Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J Infect Dis 206:1897-1903. https://doi.org/10.1093/infdis/jis620.
44. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. 2007. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 42:563-570. https://doi.org/10.1016/j.exger.2007.01.005.
45. Schulz AR, Malzer JN, Domingo C, Jurchott K, Grutzkau A, Babel N, Nienen M, Jelinek T, Niedrig M, Thiel A. 2015. Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol 195:4699-4711. https://doi.org/10.4049/jimmunol.1500598.
46. + T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog 8:e1003076. https://doi.org/10.1371/journal.ppat.1003076.
47. + T cells. PLoS Pathog 9:e1003635. https://doi.org/10.1371/journal.ppat.1003635.
48. Nakayamada S, Takahashi H, Kanno Y, O'Shea J. 2012. Helper T cell diversity and plasticity. Curr Opin Immunol 24:297-302. https://doi.org/10.1016/j.coi.2012.01.014.
49. Schwele S, Fischer A, Brestrich G, Wlodarski M, Wagner L, Schmueck M, Roemhild A, Thomas S, Hammer M, Babel N, Kurtz A, Maciejewski J, Reinke P, Volk HD. 2012. Cytomegalovirus-specific regulatory and effector T cells share TCR clonality-possible relation to repetitive CMV infections. Am J Transplant 12:669-681. https://doi.org/10.1111/j.1600-6143.2011.03842.x.
50. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. 2007. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81:8468-8476. https://doi.org/10.1128/JVI.00228-07.
51. + T cells with diverse cytokine profiles. Nat Med 11:1113-1117. https://doi.org/10.1038/nm1293.
52. + T cells targeted to vascular endothelium. PLoS Pathog 12:e1005832. https://doi.org/10.1371/journal.ppat.1005832.
53. Noriega V, Redmann V, Gardner T, Tortorella D. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol Res 54: 140-151. https://doi.org/10.1007/s12026-012-8304-8.
54. + T cells. J Virol 88:10894-10908. https://doi.org/10.1128/JVI.01477-14.
55. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. 1994. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106-109. https://doi.org/10.1126/science.8016643.
56. Sinclair J, Reeves M. 2014. The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol 5:389. https://doi.org/10.3389/fmicb.2014.00389.
57. Wills MR, Poole E, Lau B, Krishna B, Sinclair JH. 2015. The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? Cell Mol Immunol 12:128-138. https://doi.org/10.1038/cmi.2014.75.
58. Moore KW, de Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765. https://doi.org/10.1146/annurev.immunol.19.1.683.
59. Janetzki S, Rueger M, Dillenbeck T. 2014. Stepping up ELISpot: multilevel analysis in FluoroSpot assays. Cells 3:1102-1115. https://doi.org/10.3390/cells3041102.
60. Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B. 2014. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. J Immunol Methods 408:101-113. https://doi.org/10.1016/j.jim.2014.05.011.
61. Colonna-Romano G, Akbar AN, Aquino A, Bulati M, Candore G, Lio D, Ammatuna P, Fletcher JM, Caruso C, Pawelec G. 2007. Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. Exp Gerontol 42:995-1002. https://doi.org/10.1016/j.exger.2007.05.006.
62. + T cells in immunity to viruses. Nat Rev Immunol 12:136-148. https://doi.org/10.1038/nri3152.
63. Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC. 2002. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol 76:10929-10941. https://doi.org/10.1128/JVI.76.21.10929-10941.2002.
64. + T cells. Nat Med 5:1039-1043. https://doi.org/10.1038/12478.
65. Odeberg J, Plachter B, Brandén L, Söderberg-Nauclér C. 2003. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood 101: 4870-4877. https://doi.org/10.1182/blood-2002-05-1504.
66. Beck K, Meyer-König U, Weidmann M, Nern C, Hufert FT. 2003. Human cytomegalovirus impairs dendritic cell function: a novel mechanism of human cytomegalovirus immune escape. Eur J Immunol 33:1528-1538. https://doi.org/10.1002/eji.200323612.
67. Cebulla C, Miller D, Zhang Y, Rahill B, Zimmerman P, Robinson J, Sedmak D. 2002. Human cytomegalovirus disrupts constitutive MHC class II expression. J Immunol 169:167-176. https://doi.org/10.4049/jimmunol.169.1.167.
68. Verma S, Weiskopf D, Gupta A, McDonald B, Peters B, Sette A, Benedict CA. 2015. Cytomegalovirus-specific CD4 T cells are cytolytic and mediate vaccine protection. J Virol 90:650-658. https://doi.org/10.1128/JVI.02123-15.
69. + T cells despite late downregulation of MHC class II molecules. J Gen Virol 87:1853-1862. https://doi.org/10.1099/vir.0.81595-0.
70. Gibson L, Barysauskas CM, McManus M, Dooley S, Lilleri D, Fisher D, Srivastava T, Diamond DJ, Luzuriaga K. 2015. Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection. J Clin Immunol 35:289-301. https://doi.org/10.1007/s10875-015-0139-3.
71. Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, Solana R. 2015. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas 82:50-55. https://doi.org/10.1016/j.maturitas.2015.05.004.